<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01167582</url>
  </required_header>
  <id_info>
    <org_study_id>0220090205</org_study_id>
    <secondary_id>1RC2HL101458-01</secondary_id>
    <nct_id>NCT01167582</nct_id>
  </id_info>
  <brief_title>Myocardial Ischemia and Transfusion Pilot</brief_title>
  <acronym>MINT Pilot</acronym>
  <official_title>Myocardial Ischemia and Transfusion Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate two approaches to red blood cell transfusion in
      anemic patients with acute coronary syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Red blood cell transfusions are extremely common medical interventions, yet, it remains
      unclear when patients should be transfused. This pilot study will evaluate the feasibility of
      conducting a research protocol that will lead to a large scale clinical trial designed to
      evaluate the treatment effectiveness of two transfusion threshold strategies in patients with
      coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trial Feasibility</measure>
    <time_frame>6 months</time_frame>
    <description>the number of eligible study subjects and enrollment rates, overall and by center;
the adherence rates for the transfusion protocol, overall and by center;
the frequencies of proposed outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin Concentration</measure>
    <time_frame>In-hospital up to 30 days post randomization</time_frame>
    <description>Differences in the mean hemoglobin concentrations between the two study arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red Blood Cell Transfusion</measure>
    <time_frame>In-hospital up to 30 days post randomization</time_frame>
    <description>Differences in mean number of units of red blood cell transfusions between the two study arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality or Myocardial Ischemia</measure>
    <time_frame>30 days</time_frame>
    <description>Composite 30 day rates of all cause 30 day mortality, or myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction) up to 30 days after randomization, or unscheduled coronary revascularization within 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality or Myocardial Ischemia</measure>
    <time_frame>6 months</time_frame>
    <description>Composite 6 month rates of all cause 6 month mortality, recurrent myocardial infarction up to 6 months after randomization, unscheduled coronary revascularization within 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Components of Composite Outcome</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>All cause mortality Myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction) Unscheduled coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality From Cardiac Causes</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unscheduled Hospital Admission</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Unscheduled hospital admission at 30 days and 6 months for any reason, for cardiac reason (e.g., acute coronary syndrome, MI, congestive heart failure, or arrhythmia), or infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive Heart Failure</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis and Pulmonary Embolism</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia or Blood Stream Infection and Each Separately</measure>
    <time_frame>30 days and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Mortality and Morbidity</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Composite rates of all cause mortality, or myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction), or unscheduled coronary revascularization and pneumonia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Liberal Transfusion Strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restrictive transfusion strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.
Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Red blood cell transfusion</intervention_name>
    <description>Liberal versus restrictive transfusion</description>
    <arm_group_label>Liberal Transfusion Strategy</arm_group_label>
    <arm_group_label>Restrictive transfusion strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or older;

          -  STEMI (ST segment elevated myocardial infarction)

          -  NSTEMI (Non ST segment elevation myocardial infarction)

          -  unstable angina

          -  stable coronary artery disease (undergoing cardiac catheterization during the index
             hospitalization);

          -  written informed consent has been obtained

          -  hemoglobin concentration less than 10 g/dL at the time of random allocation.

        Exclusion Criteria:

          -  bleeding cannot be controlled at the cardiac catheterization puncture site and/or
             require surgery to repair vessel

          -  retroperitoneal bleeding requiring surgery

          -  clinically important hemodynamic instability based on the judgment of the treating
             physician

          -  terminal malignancy or life expectancy less than 6 months

          -  scheduled for cardiac surgery within the next 30 days

          -  symptomatic at the time of randomization

          -  declines blood transfusion

          -  history of a clinically significant transfusion reaction

          -  inability to provide informed consent;

          -  enrolled in a competing study

          -  previous participation in the MINT trial

          -  any patient who in the judgment of the research team should not be enrolled in the
             trial. This would include, but not be limited to, factors such alcohol or drug
             dependence, or psychiatric illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Carson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheryl F Kelsey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Data Coordinating Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital of Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Data Coordinating Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, Srinivas V, Menegus MA, Marroquin OC, Rao SV, Noveck H, Passano E, Hardison RM, Smitherman T, Vagaonescu T, Wimmer NJ, Williams DO. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013 Jun;165(6):964-971.e1. doi: 10.1016/j.ahj.2013.03.001. Epub 2013 Apr 8.</citation>
    <PMID>23708168</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>July 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2010</study_first_posted>
  <results_first_submitted>August 14, 2014</results_first_submitted>
  <results_first_submitted_qc>August 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Jeffrey L Carson, MD</investigator_full_name>
    <investigator_title>Jeffrey L Carson</investigator_title>
  </responsible_party>
  <keyword>blood transfusion</keyword>
  <keyword>red blood cell transfusion</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liberal Transfusion Strategy</title>
          <description>Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.</description>
        </group>
        <group group_id="P2">
          <title>Restrictive Transfusion Strategy</title>
          <description>Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.
Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized patients</population>
      <group_list>
        <group group_id="B1">
          <title>Liberal Transfusion Strategy</title>
          <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
        </group>
        <group group_id="B2">
          <title>Restrictive Transfusion Strategy</title>
          <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="13.6"/>
                    <measurement group_id="B2" value="74.3" spread="11.1"/>
                    <measurement group_id="B3" value="70.8" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trial Feasibility</title>
        <description>the number of eligible study subjects and enrollment rates, overall and by center;
the adherence rates for the transfusion protocol, overall and by center;
the frequencies of proposed outcomes</description>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin Concentration</title>
        <description>Differences in the mean hemoglobin concentrations between the two study arms.</description>
        <time_frame>In-hospital up to 30 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal Transfusion Strategy</title>
            <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Transfusion Strategy</title>
            <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Concentration</title>
          <description>Differences in the mean hemoglobin concentrations between the two study arms.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin Day 1 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.30" spread="1.00"/>
                    <measurement group_id="O2" value="9.03" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 2 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.78" spread="0.78"/>
                    <measurement group_id="O2" value="8.98" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Day 3 Post Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" spread="0.71"/>
                    <measurement group_id="O2" value="9.12" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 1 Post Randomization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Post Randomization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Post Randomization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality or Myocardial Ischemia</title>
        <description>Composite 30 day rates of all cause 30 day mortality, or myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction) up to 30 days after randomization, or unscheduled coronary revascularization within 30 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal Transfusion Strategy</title>
            <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Transfusion Strategy</title>
            <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality or Myocardial Ischemia</title>
          <description>Composite 30 day rates of all cause 30 day mortality, or myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction) up to 30 days after randomization, or unscheduled coronary revascularization within 30 days.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>5.73</ci_upper_limit>
            <estimate_desc>Restrictive Arm (numerator) compared to Liberal Arm (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality or Myocardial Ischemia</title>
        <description>Composite 6 month rates of all cause 6 month mortality, recurrent myocardial infarction up to 6 months after randomization, unscheduled coronary revascularization within 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal Transfusion Strategy</title>
            <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Transfusion Strategy</title>
            <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality or Myocardial Ischemia</title>
          <description>Composite 6 month rates of all cause 6 month mortality, recurrent myocardial infarction up to 6 months after randomization, unscheduled coronary revascularization within 6 months.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>24.7</ci_upper_limit>
            <estimate_desc>Restrictive Arm (numerator) compared to Liberal Arm (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Components of Composite Outcome</title>
        <description>All cause mortality Myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction) Unscheduled coronary revascularization.</description>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality From Cardiac Causes</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unscheduled Hospital Admission</title>
        <description>Unscheduled hospital admission at 30 days and 6 months for any reason, for cardiac reason (e.g., acute coronary syndrome, MI, congestive heart failure, or arrhythmia), or infection.</description>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Congestive Heart Failure</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Thrombosis</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deep Vein Thrombosis and Pulmonary Embolism</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pneumonia or Blood Stream Infection and Each Separately</title>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Mortality and Morbidity</title>
        <description>Composite rates of all cause mortality, or myocardial infarction (recurrent if had ST segment or Non ST segment MI or new myocardial infarction), or unscheduled coronary revascularization and pneumonia.</description>
        <time_frame>30 days and 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Red Blood Cell Transfusion</title>
        <description>Differences in mean number of units of red blood cell transfusions between the two study arms.</description>
        <time_frame>In-hospital up to 30 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liberal Transfusion Strategy</title>
            <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
          </group>
          <group group_id="O2">
            <title>Restrictive Transfusion Strategy</title>
            <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell Transfusion</title>
          <description>Differences in mean number of units of red blood cell transfusions between the two study arms.</description>
          <units>blood units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.13"/>
                    <measurement group_id="O2" value="0.49" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months following randomization</time_frame>
      <desc>Obtained via telephone follow-up and, if relevant, medical record review</desc>
      <group_list>
        <group group_id="E1">
          <title>Liberal Transfusion Strategy</title>
          <description>Patients receive red blood cell transfusion to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days</description>
        </group>
        <group group_id="E2">
          <title>Restrictive Transfusion Strategy</title>
          <description>Patients transfused if they develop symptoms related to anemia or at physician discretion if the hemoglobin concentration falls below 8 g/dL.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death at 6 months</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction at 30 days</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure at 30 Days</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This pilot trial was not designed to enroll enough patients to answer the transfusion dilemma currently facing clinicians in practice.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jeffrey Carson</name_or_title>
      <organization>Rutgers University</organization>
      <phone>732-235-7122</phone>
      <email>jeffrey.carson@rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

